MLchartDataset catalogue

hu14.18-interleukin-2 fusion protein

Term · Oncology and biomedicine · MLC-T-ONC-003994

An anticancer drug in which hu14.18, a monoclonal antibody, is combined with interleukin-2. The monoclonal antibody binds to the cancer cells and delivers IL-2, which stimulates the immune system to destroy the cancer cells.

Table 1. Record
IdentifierMLC-T-ONC-003994
FieldOncology and biomedicine
ReferencesNCI Dictionary of Cancer Terms
Record as JSON 
{
  "id": "MLC-T-ONC-003994",
  "term": "hu14.18-interleukin-2 fusion protein",
  "field": "Oncology and biomedicine",
  "definition": "An anticancer drug in which hu14.18, a monoclonal antibody, is combined with interleukin-2. The monoclonal antibody binds to the cancer cells and delivers IL-2, which stimulates the immune system to destroy the cancer cells.",
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/hu14-18-interleukin-2-fusion-protein/"
}

Record 8,714 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.